Phase III Randomized Trial of Maintenance Taxanes Versus Surveillance in Women With Advanced Ovarian/Tubal/Peritoneal Cancer: A Gynecologic Oncology Group 0212:NRG Oncology Study
暂无分享,去创建一个
R. Burger | D. Cella | P. Disaia | D. Miller | R. Mannel | M. Brady | W. Lowery | N. Spirtos | G. Glaser | S. Lele | D. O’Malley | K. Tewari | F. Ueland | L. Copeland | S. Guntupalli | Helen Q. Huang | D. Street | D. Bender | S. Dewdney | R. Morris | W. Rodgers | D. Miller | R. Morris
[1] A. Jemal,et al. Cancer Statistics, 2021 , 2021, CA: a cancer journal for clinicians.
[2] B. Monk,et al. Overall survival results of AGO-OVAR16: A phase 3 study of maintenance pazopanib versus placebo in women who have not progressed after first-line chemotherapy for advanced ovarian cancer. , 2019, Gynecologic oncology.
[3] N. Senzer,et al. Phase I Study of CT-2103, A Polymer-Conjugated Paclitaxel, and Carboplatin in Patients with Advanced Solid Tumors , 2005, Cancer investigation.
[4] D. Fishman,et al. Psychometric evaluation of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group—Neurotoxicity (Fact/GOG‐Ntx) questionnaire for patients receiving systemic chemotherapy , 2003, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.
[5] Anastasios A. Tsiatis,et al. Group sequential designs for one-sided and two-sided hypothesis testing with provision for early stopping in favor of the null hypothesis , 1994 .
[6] S. Pocock,et al. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. , 1975, Biometrics.